Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fluvoxamine as a Treatment for Long COVID-19: A Randomized Placebo Controlled Trial

NCT05874037 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05874037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05874037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fluvoxamine as a Treatment for Long COVID-19: A Randomized Placebo Controlled Trial
Lead sponsor
Washington University School of Medicine
Phase
Phase 2/3
Overall status
Completed
Start date
May 15, 2023
Completion date
March 15, 2025
Enrollment
191 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long covid